Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

17 févr. 2011 09h51 HE | Source: Bio Green Med Solution, Inc.

Data Published in the Proceedings of the National Academy of Sciences Highlight the Potential of Cyclacel's Targeted CDK Inhibitors in Breast Cancer

BERKELEY HEIGHTS, N.J., Feb. 17, 2011 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced the publication of preclinical data in...
01 févr. 2011 07h00 HE | Source: Bio Green Med Solution, Inc.

Cyclacel Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference

BERKELEY HEIGHTS, N.J., Feb. 1, 2011 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP), ("Cyclacel" or the "Company") today announced that the Company will present...
11 janv. 2011 07h00 HE | Source: Bio Green Med Solution, Inc.

Cyclacel Begins Pivotal Phase 3 "SEAMLESS" Trial of Sapacitabine as Front-Line Treatment for AML Under a Special Protocol Assessment

BERKELEY HEIGHTS, N.J., Jan. 11, 2011 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), today announced that it has opened enrollment of...
06 janv. 2011 07h00 HE | Source: Bio Green Med Solution, Inc.

Cyclacel Reviews 2010 Achievements and Key Clinical Development Objectives for 2011

BERKELEY HEIGHTS, N.J., Jan. 6, 2011 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") today reviewed 2010 achievements and outlined the...
21 déc. 2010 09h53 HE | Source: Bio Green Med Solution, Inc.

Cyclacel Announces Topline Results From the Appraise Phase 2b Study of Seliciclib in Heavily-Pretreated Patients With Non-Small Cell Lung Cancer

BERKELEY HEIGHTS, N.J., Dec. 21, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing...
05 déc. 2010 18h00 HE | Source: Bio Green Med Solution, Inc.

Cyclacel's Second Generation Cyclin-Dependent Inhibitor CYC065 Demonstrates Activity in Multiple Myeloma

BERKELEY HEIGHTS, N.J., Dec. 5, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
04 déc. 2010 17h30 HE | Source: Bio Green Med Solution, Inc.

Cyclacel Reports Phase 2 Survival Data With Sapacitabine in Myelodysplastic Syndromes at 2010 ASH Annual Meeting

BERKELEY HEIGHTS, N.J., Dec. 4, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel") announced today 1-year survival data from a Phase 2 randomized trial...
19 nov. 2010 09h00 HE | Source: Bio Green Med Solution, Inc.

Cyclacel Pharmaceuticals to Present Sapacitabine Phase 2 MDS Data at the Upcoming American Society of Hematology Meeting

BERKELEY HEIGHTS, N.J., Nov. 19, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP), a biopharmaceutical company developing oral therapies that target the various...
12 nov. 2010 09h37 HE | Source: Bio Green Med Solution, Inc.

Cyclacel to Present at Upcoming Conferences

BERKELEY HEIGHTS, N.J., Nov. 12, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP), a biopharmaceutical company developing oral therapies that target the various...
11 nov. 2010 16h01 HE | Source: Bio Green Med Solution, Inc.

Cyclacel Pharmaceuticals Reports Third Quarter 2010 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 11, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP), a biopharmaceutical company developing oral therapies that target the various...

Page précédente